Aurinia Presents Breadth Of Data At ASN 2023 Demonstrating Clinical Importance Of LUPKYNIS For Managing Lupus Nephritis
Portfolio Pulse from Benzinga Newsdesk
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) presented nine studies at the annual American Society of Nephrology Kidney Week 2023, reinforcing the safety and effectiveness of LUPKYNISⓇ (voclosporin) for the treatment of adult patients with active Lupus Nephritis (LN). The studies showed that patients treated with LUPKYNISⓇ achieved improvement in histologic activity with stable chronicity scores and no evidence of chronic injury. The data also suggested that LUPKYNISⓇ plus standard of care improved safety and demonstrated earlier reductions in proteinuria compared to a conventional regimen. A post-hoc analysis showed Black patients experienced improved outcomes and better renal response when using LUPKYNISⓇ.

November 02, 2023 | 10:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The presented studies reinforce the safety and effectiveness of Aurinia's LUPKYNISⓇ for the treatment of Lupus Nephritis, which could potentially boost the company's reputation and sales.
The positive data presented at a major conference about Aurinia's product LUPKYNISⓇ could potentially increase the product's adoption by healthcare providers, leading to increased sales and a positive impact on the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100